Health Law Update

Home | Health Law Update

On Friday, April 7, both the Northern District of Texas and the Eastern District of Washington issued decisions impacting the FDA approval of the abortion drug mifepristone. The Texas decision blocks prescribing and dispensing of mifespristone nationwide, while the Washington decision enjoins the FDA from altering the status quo related to mifepristone. The discrepancy is likely to escalate to the Supreme Court of the United States for review.

core/paragraph

<a href="https://www.bakerlaw.com/insights/challenge-to-the-fdas-approval-of-abortion-medication/">Read the full alert.</a>

Challenge to the FDA’s Approval of Abortion Medication